Evidence map›Paper›PMID 19016326›Full record

ArticleDigestive diseases and sciences2009

Progression of hypermethylation of the p16(INK4A) gene from normal liver to nontumorous liver and hepatocellular carcinoma: an evaluation using quantitative PCR analysis.

So Kurita, Shogo Ohkoshi, Masahiko Yano, Kazuhide Yamazaki, Kenta Suzuki, Yo-hei Aoki, Yasunobu Matsuda, Toshifumi Wakai, Yoshio Shirai, Takafumi Ichida and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

So KuritaDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences of Niigata University, 1-754, Asahimachi-Dori, Niigata-city, 951-8122, Japan.
Shogo Ohkoshi
Masahiko Yano
Kazuhide Yamazaki
Kenta Suzuki
Yo-hei Aoki
Yasunobu Matsuda
Toshifumi Wakai
Yoshio Shirai
Takafumi Ichida
Yutaka Aoyagi
Niigata University · JPNiigata University Medical and Dental Hospital · JPJuntendo University Shizuoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to determine to what extent hypermethylation of the p16(INK4A) (p16) gene promoter is increased in nontumorous liver tissues compared with in normal liver, using two quantitative methylation-specific polymerase chain reaction (MS-PCR) methods and a bisulfite sequencing method. Methylation of the p16 gene was detected more frequently in nontumorous liver than in normal liver using the TaqMan PCR method. Methylation indices also were significantly higher in nontumorous than in normal liver. However, the bisulfite sequencing method did not detect significantly more methylation of the p16 gene in nontumorous than normal liver, nor was there a significant difference in the level of p16 mRNA. There may be a greater proportion of cells which contain methylated p16 in nontumorous than in normal liver. However, the difference was so small that the functional relevance to hepatocarcinogenesis remains elusive.

Indexed as

AllelesBase SequenceCarcinoma, HepatocellularCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDNA MethylationFemaleHumansLiverLiver NeoplasmsMaleMiddle AgedMolecular Sequence DataPolymerase Chain ReactionPrecancerous ConditionsRNA, MessengerCyclin-Dependent Kinase Inhibitor p16RNA, Messenger

Identifiers

PMID19016326
OpenAlexW1964270383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.